Offerings
- - - Lifesciences Nucleosides
      
      Specialty Chemicals
      
      CDMO
  - - From research and development to manufacturing at scale, our teams have demonstrated leading capabilities in Nucleic acid chemistry. Some of the most respected companies in the space of pharma, biopharma, drug discovery and oligo-manufacturing repose an abiding trust in our chemistry prowess to be more agile and ahead.
      
      Know more
    - The specialty chemicals industry in India is poised for significant growth, driven by increased demand from both domestic and international markets. With emphasis on innovation and sustainability as critical growth factors, Innovassynth is geared to meet the emerging global needs with cost-competitive production capabilities and adherence to stringent global quality standards.
      
      Know more
    - At Innovassynth, we bring the “Chemistry of Possibilities” to life, transforming your vision into reality through our custom development and manufacturing services. As a leading provider in the life sciences and specialty chemical industries, our state-of-the-art infrastructure and expert team are dedicated to delivering bespoke solutions that meet your unique needs.
      
      Know more
Infrastructure
Why Us
Commitment
Investor Relations
Careers
About Us
Contact Us

Investors Complaints

INVESTOR RELATIONS

Investors Complaints

Investor Complaints (Regulation 13(3) of SEBI LODR)

SELECT A YEAR:FY 2024-25 FY 2023-24 FY 2022-23 FY 2021-22 Other FY 2018-19 FY 2016-17 FY 2018 FY 2016 FY 2015-16

FY 2024-25

First Quarter

Investor Complaints 30.06.2024

Second Quarter

Investor Complaints 30.09.2024

Third Quarter

Investor Complaints 31.12.2024

Fourth Quarter

Investor Complaints 31.03.2025

FY 2023-24

First Quarter

Investor Complaints 30.06.2023

Second Quarter

Investor Complaints 30.09.2023

Third Quarter

Investor Complaints 31.12.2023

Fourth Quarter

Investor Complaints 31.03.2024

FY 2022-23

Third Quarter

Investors Complaints 31.12.2022

Fourth Quarter

Investors Complaints 31.03.2023

FY 2021-22

First Quarter

REG 13(3) – Investor Complaints Q1 2021-22 FY21-22 – Q1

Second Quarter

REG 13(3) – Investor Complaints Q2 2021-22 FY21-22 – Q2

Third Quarter

REG 13(3) – Investor Complaints Q3 2021-22

Fourth Quarter

Q4 Investor Complaints INNOVA 13(3)

Other

First Quarter

REG 13(3) – Investor Complaints Q1 Q1 – REG 13(3) Investor Complaints Report U.R 13(3) of LODR June Q1

Second Quarter

REG 13(3) – Investor Complaints Q2 Q2 – REG 13(3) Investor Complaints Reg 13 (3) Q2 Regulation 13 (3) of LODR September Q2

Third Quarter

REG 13(3) – Investor Complaints Q3 Q3 – REG 13(3) Investor Complaints Investor Complaint Q3 Regulation 13(2) Q3

Fourth Quarter

REG 13(3) – Investor Complaints Q4 Q4 – REG 13(3) Investor Complaints Compliance Certificate – RTA Q4 Regulation 13 (3) Q4

FY 2018-19

First Quarter

Investor Complaint June 2018 Q1

Second Quarter

Investor Complaints Q2 Sept 2018

FY 2016-17

First Quarter

Regulation 13(3) 30.06.2017 Q1

FY 2018

Third Quarter

Investor Complaints 160118 Q3

Fourth Quarter

Investor Complaints March 2018 Q4

FY 2016

Third Quarter

Regulation 13(3) 31.12.2016 Q3

FY 2015-16

Fourth Quarter

Regulation 13(3) 31.03.2016 Q4

Registered Office
Innovassynth Technologies (India) Limited
(formerly known as Innovassynth Investments Limited)
Old Mumbai-Pune Road, Khopoli, Raigarh (MH), Khopoli – 410 203, Maharashtra, India
CIN: L67120MH2008PLC178923

Tel: +91-2192-260100

secretarial@innovassynth.com

Offerings

Quick Links

Commitment

© All Copyright 2024 by Innovassynth Technologies (India) Ltd.